Suppr超能文献

合成的Toll样受体7和8激动剂:氧代腺嘌呤系列中的构效关系。

Synthetic Toll-like Receptors 7 and 8 Agonists: Structure-Activity Relationship in the Oxoadenine Series.

作者信息

Evans Jay T, Bess Laura S, Mwakwari Sandra C, Livesay Mark T, Li Yufeng, Cybulski Van, Johnson David A, Bazin Hélène G

机构信息

GSK Vaccines, 553 Old Corvallis Road, Hamilton, Montana 59840, United States.

Division of Biological Sciences and Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana 59802, United States.

出版信息

ACS Omega. 2019 Sep 10;4(13):15665-15677. doi: 10.1021/acsomega.9b02138. eCollection 2019 Sep 24.

Abstract

Toll-like receptors 7 and 8 (TLR7/8) are broadly expressed on antigen-presenting cells, making TLR7/8 agonists likely candidates for the development of new vaccine adjuvants. We previously reported the synthesis of a new series of 8-oxoadenines substituted at the 9-position with a 4-piperidinylalkyl moiety and demonstrated that TLR7/8 selectivity and potency could be modulated by varying the length of the alkyl linker. In the present study, we broadened our initial structure-activity relationship study to further evaluate the effects of N-heterocycle ring size, chirality, and substitution on TLR7/8 potency, receptor selectivity, and cytokine (IFNα and TNFα) induction from human peripheral blood mononuclear cells (PBMCs). TLR7/8 activity correlated primarily to linker length and to a lesser extent to ring size, while ring chirality had little effect on TLR7/8 potency or selectivity. Substitution of the heterocyclic ring with an aminoalkyl or hydroxyalkyl group for subsequent conjugation to phospholipids or antigens was well tolerated with the retention of both TLR7/8 activity and cytokine induction from human PBMCs.

摘要

Toll样受体7和8(TLR7/8)在抗原呈递细胞上广泛表达,这使得TLR7/8激动剂成为新型疫苗佐剂开发的潜在候选物。我们之前报道了一系列在9位被4-哌啶基烷基部分取代的新型8-氧代腺嘌呤的合成,并证明可以通过改变烷基连接子的长度来调节TLR7/8的选择性和效力。在本研究中,我们扩展了最初的构效关系研究,以进一步评估N-杂环环大小、手性和取代对TLR7/8效力、受体选择性以及人外周血单个核细胞(PBMC)中细胞因子(IFNα和TNFα)诱导的影响。TLR7/8活性主要与连接子长度相关,在较小程度上与环大小相关,而环手性对TLR7/8效力或选择性影响很小。用氨基烷基或羟烷基取代杂环以便随后与磷脂或抗原偶联,在保留TLR7/8活性和人PBMC细胞因子诱导能力的情况下耐受性良好。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99a7/6761749/87d5ba7de4a3/ao9b02138_0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验